MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2023 International Congress

    SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models

    M. Castelo, G. Gentile, A. Zanon, A. Lavdas, C. Bolduc, M. Picon, S. Laouafa, J. Soliz, M. Lévesque, I. Pichler (Bolzano, Italy)

    Objective: Validate the rescue potential of SLP-2 induction for α-synuclein (aSyn)-induced mitochondrial pathology and neurodegeneration in two complementary models: human induced pluripotent stem cell (hiPSC)-derived…
  • 2023 International Congress

    The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson’s Disease Pathogenesis

    MG. Jo, BN. Lee, HM. Seong, SH. Kim, HN. Choi, MG. Kim, SP. Yun (Jinju, Republic of Korea)

    Objective: We investigated whether α-synuclein-derived peptides (recognized specific sequence in α-synuclein) can drive T-cell response and evaluated the neurotoxicity of α-synuclein peptide-specific T-cell in Parkinson’s…
  • 2023 International Congress

    Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease

    S H. Diaw, F. Buratti, L. Streubel-Gallasch, M. Borsche, M. Dulovic-Mahlow, C O. Fernández, J. Seeliger, I. Lenz, P. Seibler, C. Klein, N. Brüggemann, M. Zweckstetter, M. Vos, K. Lohmann (Lübeck, Germany)

    Objective: To investigate functional alterations of the p.V15A variant in alpha-Synuclein (α-Syn) in Parkinson's disease (PD). Background: PD is marked by the loss of dopaminergic…
  • 2023 International Congress

    The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease

    E. Gök Dursun, M. Karataş, M. çetinkaya, K. Karlı Oğuz, B. Tel, G. Yalçın çakmaklı, B. Elibol (Ankara, Turkey)

    Objective: The aim of this study is to investigate the contribution of the glymphatic system to the pathophysiology of Parkinson's disease (PD). Background: Neurotoxicity of…
  • 2023 International Congress

    PASADENA 1-year open-label extension

    G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…
  • 2023 International Congress

    An SNCA triplication in a Kazakhstani patient with young-onset Parkinson’s disease

    R. Kaiyrzhanov, C. Shashkin, N. Zharkinbekova, V. Akhmetzhanov, Z. Myrzayev, A. Karimova, S. Aidarov, K. Mok, H. Houlden (Shymkent, Kazakhstan)

    Objective: To report a patient with Parkinson’s disease (PD) from Kazakhstan with a rare structural defect in the SNCA gene. Background: Little is known about…
  • 2023 International Congress

    Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

    W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

    Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…
  • 2023 International Congress

    Potential role of Alpha-synuclein levels in Platelets in GBA-related PD

    G. Uras, S. Lucas, A. Schapira (London, United Kingdom)

    Objective: Identification of a blood biomarker to predict PD diagnosis or to monitor the disease progression. Background: Previous evidence suggests differences in systemic alpha-synuclein levels…
  • 2023 International Congress

    Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.

    KE. Choi, SY. Kim, J. Jang, I. Hwang, KW. Lee, JS. Kim (Seoul, Republic of Korea)

    Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…
  • 2022 International Congress

    The role of GBA1 mutations in the relationship between GBA1 and alpha-synuclein in Parkinson disease

    L. Smith, M. Gegg, D. Chau, AHV. Schapira (London, United Kingdom)

    Objective: The aim of the study was to understand how the E326K GBA1 mutation results in an increased risk for Parkinson disease, through influencing the…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley